Renal cell carcinoma epidemiology and demographics: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
{{Renal cell carcinoma}} | {{Renal cell carcinoma}} | ||
==Overview== | |||
Renal cell carcinoma is considered the 7th most common cancer in men and 9th most common cancer in women, accounting for approximately 2-3% of malignant tumors in adults. Men are twice more likely to be affected than women with an mean age of presentation at 60 years. Most renal cell carcinomas develop sporadically, while only a small number of cases are of genetic diseases. Clear cell carcinomas are the most common renal cell carcinomas and collecting-duct carcinomas are the least common. The diagnosis of renal cell carcinoma is mostly by the incidental finding of the tumor. | |||
==Epidemiology== | ==Epidemiology== | ||
Renal cell carcinomas is considered the | Renal cell carcinomas is considered the 7th most common cancer in men and the 9th most common cancer in women. It account for approximately 2-3% of all malignant tumors in the adult population.<ref name="pmid19269025">{{cite journal| author=Rini BI, Campbell SC, Escudier B| title=Renal cell carcinoma. | journal=Lancet | year= 2009 | volume= 373 | issue= 9669 | pages= 1119-32 | pmid=19269025 | doi=10.1016/S0140-6736(09)60229-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19269025 }} </ref> More than 70% of renal cell carcinomas are clear cell carcinomas. Papillary carcinomas are the second most common renal cell carcinomas. The least common types of renal cell carcinomas are collecting-duct renal cell carcinomas, accounting for less than 1% of all cases.<ref name="pmid16339096">{{cite journal| author=Cohen HT, McGovern FJ| title=Renal-cell carcinoma. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 23 | pages= 2477-90 | pmid=16339096 | doi=10.1056/NEJMra043172 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16339096 }} </ref> Most cases of renal cell carcinoma are sporadic; whereas only approximately 2-3% of all cases are familial, most of which have an autosomal-dominant pattern of inheritance.<ref name="pmid19269025">{{cite journal| author=Rini BI, Campbell SC, Escudier B| title=Renal cell carcinoma. | journal=Lancet | year= 2009 | volume= 373 | issue= 9669 | pages= 1119-32 | pmid=19269025 | doi=10.1016/S0140-6736(09)60229-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19269025 }} </ref> | ||
The male to female ratio is approximately 2 to 1.<ref name="pmid19269025">{{cite journal| author=Rini BI, Campbell SC, Escudier B| title=Renal cell carcinoma. | journal=Lancet | year= 2009 | volume= 373 | issue= 9669 | pages= 1119-32 | pmid=19269025 | doi=10.1016/S0140-6736(09)60229-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19269025 }} </ref> The ratio increases dramatically increases in sporadic cases of papillary renal cell carcinomas, reaching a 5 to 1 ratio.<ref name="pmid16339096">{{cite journal| author=Cohen HT, McGovern FJ| title=Renal-cell carcinoma. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 23 | pages= 2477-90 | pmid=16339096 | doi=10.1056/NEJMra043172 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16339096 }} </ref> The median age of presentation is typically 60 years. Presentation might range from a much more common asymptomatic course (incidental finding) to a less likely local or paraneoplastic/systemic presentation.<ref name="pmid19269025">{{cite journal| author=Rini BI, Campbell SC, Escudier B| title=Renal cell carcinoma. | journal=Lancet | year= 2009 | volume= 373 | issue= 9669 | pages= 1119-32 | pmid=19269025 | doi=10.1016/S0140-6736(09)60229-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19269025 }} </ref> | The male to female ratio is approximately 2 to 1.<ref name="pmid19269025">{{cite journal| author=Rini BI, Campbell SC, Escudier B| title=Renal cell carcinoma. | journal=Lancet | year= 2009 | volume= 373 | issue= 9669 | pages= 1119-32 | pmid=19269025 | doi=10.1016/S0140-6736(09)60229-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19269025 }} </ref> The ratio increases dramatically increases in sporadic cases of papillary renal cell carcinomas, reaching a 5 to 1 ratio.<ref name="pmid16339096">{{cite journal| author=Cohen HT, McGovern FJ| title=Renal-cell carcinoma. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 23 | pages= 2477-90 | pmid=16339096 | doi=10.1056/NEJMra043172 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16339096 }} </ref> The median age of presentation is typically 60 years. Presentation might range from a much more common asymptomatic course (incidental finding) to a less likely local or paraneoplastic/systemic presentation.<ref name="pmid19269025">{{cite journal| author=Rini BI, Campbell SC, Escudier B| title=Renal cell carcinoma. | journal=Lancet | year= 2009 | volume= 373 | issue= 9669 | pages= 1119-32 | pmid=19269025 | doi=10.1016/S0140-6736(09)60229-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19269025 }} </ref> |
Revision as of 19:15, 12 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Renal cell carcinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Renal cell carcinoma epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Renal cell carcinoma epidemiology and demographics |
Renal cell carcinoma epidemiology and demographics in the news |
Risk calculators and risk factors for Renal cell carcinoma epidemiology and demographics |
Overview
Renal cell carcinoma is considered the 7th most common cancer in men and 9th most common cancer in women, accounting for approximately 2-3% of malignant tumors in adults. Men are twice more likely to be affected than women with an mean age of presentation at 60 years. Most renal cell carcinomas develop sporadically, while only a small number of cases are of genetic diseases. Clear cell carcinomas are the most common renal cell carcinomas and collecting-duct carcinomas are the least common. The diagnosis of renal cell carcinoma is mostly by the incidental finding of the tumor.
Epidemiology
Renal cell carcinomas is considered the 7th most common cancer in men and the 9th most common cancer in women. It account for approximately 2-3% of all malignant tumors in the adult population.[1] More than 70% of renal cell carcinomas are clear cell carcinomas. Papillary carcinomas are the second most common renal cell carcinomas. The least common types of renal cell carcinomas are collecting-duct renal cell carcinomas, accounting for less than 1% of all cases.[2] Most cases of renal cell carcinoma are sporadic; whereas only approximately 2-3% of all cases are familial, most of which have an autosomal-dominant pattern of inheritance.[1]
The male to female ratio is approximately 2 to 1.[1] The ratio increases dramatically increases in sporadic cases of papillary renal cell carcinomas, reaching a 5 to 1 ratio.[2] The median age of presentation is typically 60 years. Presentation might range from a much more common asymptomatic course (incidental finding) to a less likely local or paraneoplastic/systemic presentation.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Rini BI, Campbell SC, Escudier B (2009). "Renal cell carcinoma". Lancet. 373 (9669): 1119–32. doi:10.1016/S0140-6736(09)60229-4. PMID 19269025.
- ↑ 2.0 2.1 Cohen HT, McGovern FJ (2005). "Renal-cell carcinoma". N Engl J Med. 353 (23): 2477–90. doi:10.1056/NEJMra043172. PMID 16339096.